Condition: Alzheimer Disease · Major Depressive Disorder · Sponsor: NYU Langone Health
This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers. The study involves an FDA-approved treatment for major depressive disorder. It will compare the SSRI antidepressant escitalopram with placebo. The hypothesis is that a reduction in depressive symptoms will be associated with a normalization of CSF AD biomarkers as well as peripheral inflammatory markers. This research would contribute to fundamental knowledge about potentially modifiable risks of Alzheimer's disease (AD).
This description comes directly from the study's public registry record.
Antero Sarreal, MD · 845-398-6532 · Antero.sarreal@nki.rfmh.org
Chelsea Reichert Plaska, PhD · 845-398-5583 · Chelsea.reichert@nki.rfmh.org
Always discuss trial participation with your own doctor first.
| NYU Langone Health | New York, New York, United States | Recruiting |
| Nathan S. Kline Institute for Psychiatric Research | Orangeburg, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05004987